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Summary
Pharmacogenetics is genetic testing to optimise 
prescribing for individual patients. Warfarin 
is a potential candidate for pharmacogenetic 
testing as it is commonly used, has a narrow 
therapeutic window and its mechanism of action 
and elimination pathways involve receptors and 
enzymes that are polymorphic. Polymorphism 
is found in vitamin K epoxide reductase and 
cytochrome P450 2C9. Pharmacogenetic testing 
is not yet routine because alone it does not 
predict all the variability in a patient's response 
to warfarin so its contribution to improved clinical 
outcomes is uncertain.
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Introduction 
Pharmacogenetics refers to testing based on an individual 
patient's genetic variation for the purpose of prescribing 
drug therapy. If it can successfully individualise treatment, 
pharmacogenetics could have the potential to vastly improve 
health outcomes. However, there is a long scientific journey 
from noting a genetic alteration in a drug target or metabolising 
enzyme to predicting a clinically relevant change in health 
outcomes. 
A patient's response to warfarin is influenced by their genome, 
so pharmacogenetics could be used to determine warfarin 
sensitivity. However, there are a myriad of non-genetic factors 
affecting the relationship between warfarin dose and health 
outcomes. 
Warfarin
Warfarin is the most commonly prescribed anticoagulant 
drug for the prophylaxis and treatment of venous and arterial 
thromboembolic disorders. It is now routinely used by many 
patients with atrial fibrillation. There is therefore interest in whether 
testing for genetic variations in warfarin metabolism could be 
useful for predicting the optimum dose, reducing bleeding risk 
and reducing the time to achieve a therapeutic prothrombin time 
(expressed as the international normalised ratio (INR)). 
The efficacy and safety of warfarin is critically dependent on 
maintaining the INR within the therapeutic range.1 Treatment may 
be ineffective if the INR is low, but there is a sharp increase in 
the risk of bleeding when the INR is above the upper limit of the 
therapeutic range.2 However, with current management patients 
remain on average within their target range for only two-thirds 
of the time.3 This is likely to be because current warfarin-dosing 
algorithms do not incorporate genetic and environmental factors 
that affect warfarin concentrations and effects. 
Different patients can have highly variable responses to 
the same dose of warfarin. In order to understand the wide 
inter- and intra-patient variability in response, it is necessary 
to consider the pharmacokinetics and pharmacodynamics of 
warfarin and the effect of age, size and diet.
Cytochrome P450 2C9
Warfarin is an equal mixture of the enantiomers S-warfarin 
and R-warfarin, with S-warfarin being approximately 3–5 times 
more potent than R-warfarin. Metabolism of S-warfarin occurs 
through the cytochrome P450 2C9 enzyme, while metabolism 
of the less potent R-warfarin occurs through CYP2C19, CYP1A2 
and CYP3A4 (see Fig. 1).4 
Patients who metabolise warfarin normally are homozygous 
for the usual (wild-type) allele CYP2C9*1. Two other clinically 
relevant single nucleotide polymorphisms have been identified 
in CYP2C9 (*2 and *3). These result in reduced enzymatic 
activity and therefore reduced warfarin metabolism. The  
*2/*2 homozygous genotype leads to a 12% reduction in 
CYP2C9 activity and the *3/*3 homozygous genotype has less 
than 5% of wild-type CYP2C9 activity. These single nucleotide 
polymorphisms are relatively common in Caucasians. 
Approximately 1% of the population are homozygous for 
CYP2C9*2 and 22% are heterozygous carriers of this allele. The 
corresponding figures for CYP2C9*3 are 0.4% and 15%. Another 
1.4% of people are compound heterozygotes (CYP2C9*2*3). 
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Patients requiring a low dose of warfarin (1.5 mg daily or less) 
have a high likelihood of having a CYP2C9 variant allele  
(*2 or *3) and an increased risk of major bleeding complications.5 
A number of studies have shown that knowing the patient's 
genotype helps in both predicting the optimal dose of warfarin 
and achieving the target INR more quickly.6,7,8 However, using 
this knowledge to predict dose may not necessarily reduce 
bleeding events.7
Vitamin K 2,3 epoxide reductase complex
Even after adjusting the warfarin dose for the variability in 
CYP2C9 status, there is still an amount of dosing variability 
in patients who have similar CYP2C9 alleles. This variability 
appears to be partly attributable to genetic polymorphisms in 
the C1 sub-unit of the vitamin K 2,3 epoxide reductase complex 
(VKORC1). This enzyme complex is the rate-limiting step in 
the vitamin K-dependent gamma carboxylation system which 
activates clotting factors. Warfarin exerts its anticoagulant effect 
by inhibiting VKORC1 (Fig. 1).
A number of common polymorphisms in non-coding sequences 
have been identified in VKORC1. Polymorphisms of this receptor 
are associated with a need for lower doses of warfarin (see  
Table 1).9  The VKORC1 genotype alone may explain nearly  
40% of the variability in response to warfarin.10
Other genetic mutations
It is theoretically possible that point mutations in the genes 
for CYP2C9 or VKORC1 add to the variability in warfarin 
requirements when patients start therapy. There are at least two 
models which have demonstrated that the CYP2C9 and VKORC1 
genotypes, together with known factors such as age and body 
size, only explain half to two-thirds of the inter-individual 
variability in warfarin requirements.8,11 Although this is an 
improvement on current non-pharmacogenetic algorithms, at 
least one-third of the variability is still unaccounted for. There 
are at least 30 other genes involved in the pharmacodynamics 
of warfarin which may explain this variability, including 
polymorphisms in apolipoprotein E, multidrug resistance 1 
(MDR1), genes encoding vitamin K-dependent clotting factors and 
possibly genes encoding additional components of the vitamin K 
epoxide reductase complex. 
environmental factors that affect warfarin 
dosage requirements 
One of the difficulties with focusing solely on the effect of 
polymorphisms in the metabolising pathways of S-warfarin and 
vitamin K is that there are a number of non-genetic factors that 
affect the INR (Tables 1 and 2). Age, racial group and sex are 
well known, but increasingly recognised yet understudied is the 
effect of dietary and gut-derived vitamin K. 
Vitamin K
Vitamin K is an essential cofactor for the normal production of 
clotting factors II, VII, IX and X. By inhibiting VKORC1, warfarin 
reduces the regeneration of vitamin K and thereby inhibits the 
activation of vitamin K-dependent clotting factors. It is known 
that a patient's vitamin K status when starting warfarin affects 
the time to reach a therapeutic INR. In addition, a daily dietary 
intake of more than 250 microgram reduces warfarin sensitivity. 
Interesting from a therapeutic perspective is the finding that 
giving patients with an unstable INR daily doses of vitamin K 
150 microgram decreases the variability of INR and increases 
the time in the target range.12
Fig. 1
Schematic diagram of the action of warfarin
Warfarin is administered as a racemic mixture of S and R enantiomers. Cytochrome P450 2C9 inactivates the more potent 
S-warfarin enantiomer. Warfarin inhibits vitamin K epoxide reductase, preventing recycling of vitamin K leading to partially 
carboxylated sub- or non-functional coagulation proteins.
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Is pharmacogenetic testing appropriate when 
prescribing warfarin?
Clinicians require easily available information that can help 
them to predict an individual's warfarin requirements with close 
to 100% accuracy in both the induction and maintenance phases 
of therapy. This is especially relevant when starting treatment as 
this is when the risk of bleeding due to over-anticoagulation is 
high. The induction regimens in current use (such as modified 
Fennerty regimens13) are only partly successful in achieving the 
target INR, especially in older people.14 
Knowing the patient's CYP2C9 and VKORC1 status predicts less 
than half of the variation in the response to warfarin. Better 
predictions are achieved by incorporating pharmacogenetics 
into a dosing algorithm such as that based on the regression 
model of Sconce.11 In this model the variables age, height, and 
the CYP2C9 and VKORC1 genotypes were the best predictors 
for estimating the starting dose of warfarin. This algorithm also 
confirmed that the mean warfarin daily dose requirement would 
be significantly lower with some genotypes.
As an example of the model's utility, the estimated daily 
Table 1
Factors associated with lower warfarin requirements
Factor effect
Age Reduced requirements with age may be secondary to smaller liver size with age
Reduced vitamin K intake,  
   e.g. starvation
Inadequate vitamin K to activate clotting factors
Genotypes
VKORC1 3673 The AA genotype affects warfarin requirement less than GA or GG genotypes
CYP2C9 *2 or *3
CYP2C9 *2 and *3
Both heterozygotes of *2 or *3, or homozygotes of *2 and *3 result in reduced warfarin  
   requirements
medical conditions
Advanced malignancy Reduced requirements may be due to liver metastases, lower body weight and drug interactions
Malabsorption syndromes Affects vitamin K production and absorption in gut
Liver disease Affects synthetic functions of liver including production of clotting factors and warfarin metabolism
Heart disease Causes hepatic congestion, resulting in abnormal liver function and reduced clotting factor  
   synthesis
Pyrexia Increases warfarin sensitivity by enhancing the rate of degradation of vitamin K-dependent  
   clotting factors
Hyperthyroidism Thyroxine increases the affinity of warfarin for receptor sites, decreasing production of  
   vitamin K-dependent clotting factors. It also catabolises these factors more quickly.
Some racial groups May be independent or secondary to known racially divergent CYP2C9 or VKORC1 mutations,  
   different diet or additional factor
Gender Gender did not make any significant contribution to the regression models, but it is likely that  
   the differences in warfarin requirements noted clinically are attributable to females' smaller  
   body size
Factor VII deletion genotype Mildly lower reduction
Factor X insertion genotype Small reduction
VKORC1 vitamin K epoxide reductase
CYP cytochrome P450
Table 2
Factors associated with higher warfarin requirements
Factor effect
Increased body  
  weight
Higher total and lean body weight  
  increase warfarin requirements,  
  possibly through their effect on  
  increasing body surface area
Smoking Increased metabolism, particular of  
  the R-enantiomer
Cytochrome  
  P450 2C9 inducers
Induce metabolism of the  
  S-enantiomer
High dietary  
  vitamin K
Difficulty of carboxylating clotting  
  factors with warfarin
Hypothyroidism Decreased catabolism of vitamin K- 
  dependent clotting factors
warfarin dosage requirement for a 170 cm tall, 90-year-old man 
with CYP2C9*1/*3 and VKORC1-AA genotypes is more than 
six times lower than that for a 30-year-old patient of the same 
height with the CYP2C9 wild type and VKORC1-GG genotypes.  
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This model is a marked improvement on current algorithms, 
but it still only explains 55% of the variability in dose 
requirements. However, a recent paper has shown that, despite 
the shortcomings, a pharmacogenetics algorithm is clinically 
helpful to predict appropriate initial doses of warfarin in high-
risk patients.15
Cost-effectiveness
As with all new technologies, it is important to evaluate the 
incremental cost-effectiveness of pharmacogenetics testing 
versus standard clinical practice. Pharmacogenetic testing 
for warfarin is relatively cheap compared to other new health 
technologies. The extra costs of this service include the 
polymerase chain reaction tests for the three CYP and two 
VKORC genes and the costs of clinical interpretation, estimated 
at $75–80 per person, with a turnaround time of three hours. The 
efficacy of the tests is measured as the reduction in the number 
of expensive adverse effects, time in hospital and improvement 
in quality of life due to less frequent INR monitoring. None of 
this has been accurately quantified in a prospective study, yet it 
is clear that even a reduction in hospital stay by one day would 
provide a sizeable cost offset. However, while testing seems 
relatively good value for money, there are additional issues to 
consider, for example the cost of screening all potential warfarin 
users. Additionally, although the prevalence of heterozygotes is 
relatively high (approximately 30% for CYP2C9), patients with a 
null genotype (those likely to get life-threatening and expensive 
adverse effects) are rare (less than 1%). The detection rate for a 
genotype associated with serious adverse events is therefore 
low. Lastly, we know that clinical outcomes such as bleeding 
are rare in patients followed in anticoagulation clinics because 
warfarin therapy is closely monitored and individualised. The 
INR is a well-validated and inexpensive surrogate marker for 
warfarin effects which is already in clinical practice. However, 
it is not helpful for predicting which dose of warfarin to use for 
starting anticoagulation. 
Additional epidemiological studies are needed to assess the 
association between genotype and the absolute risk of adverse 
effects before a cost-effectiveness analysis can be completed.16 
Conclusion
The variability in warfarin dosage requirements is multifactorial, 
although genetic polymorphisms play a part. Current warfarin-
dosing algorithms fail to take into account genetics and 
other individual patient factors. Theoretically, including these 
factors could help in predicting an individual's loading and 
maintenance doses for safer anticoagulation. However, linear 
regression analysis, taking into account genetic polymorphisms 
of CYP2C9 and VKORC1 (additive effect), body weight, body 
surface area and height, has so far been able to capture only 
approximately half of the large inter- and intra-patient variation 
in dose requirements. Vitamin K status and alcohol intake, 
together with additional genetic factors, are likely to account 
for some of the remaining difference in warfarin requirements, 
but still need to be studied in a regression analysis. For now, 
incorporation of age, body surface area, CYP2C9 and VKORC1 
genotype allow the best estimate of warfarin induction and 
maintenance dose. 
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Self-test questions
The following statements are either true or false  
(answers on page 87)
7. Increased dietary intake of vitamin K reduces a patient's 
warfarin requirements.
8. Most of the inter-individual variation in warfarin 
requirements can be explained by genetic variation in 
cytochrome P450 2C9.
Dental notes
Prepared by Michael McCullough, Chair, 
Therapeutics Committee, Australian Dental 
Association
Pharmacogenetics of warfarin 
The international normalised ratio (INR) is a simple test 
commonly used by dentists to gauge the likelihood that a 
patient taking warfarin will have excessive haemorrhage 
following tooth extraction. There is a clearly defined range of 
INR values within which simple local post-extraction measures, 
such as suturing, pressure and tranexamic acid mouth rinses, 
are adequate to control bleeding. Patients within this range can 
continue warfarin.1 
The large variation in INR values, related to genetic and dietary 
factors, particularly the intake of vitamin K, reinforces the need 
to have this test undertaken shortly before the dental procedure.
The metabolism of warfarin can be reduced by azole antifungals 
such as miconazole. Topical oral miconazole can profoundly 
increase the INR and thus the risk of bleeding due to over-
anticoagulation.2,3 Similarly metronidazole, which is commonly 
used in the management of oral infections, can greatly increase 
the INR. Dentists therefore need to review patients' current 
medication before prescribing any drugs, even those topically 
applied, for possible interactions with warfarin.
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New drugs: transparency
Access to information about drugs is essential for the quality 
use of medicines. Since 2003 Australian Prescriber has therefore 
recorded details about the willingness of pharmaceutical 
companies to disclose the information that supported the 
Australian approval of their new products.1 These details are 
published as the T(ransparency)-score at the end of each new 
drug comment in Australian Prescriber. 
Table 1 shows the responses to requests for evaluation 
data between January 2007 and January 2009. The Editorial 
Executive Committee of Australian Prescriber is pleased to 
report that there has been an improvement since the previous 
reports were published.1,2 Most manufacturers now provide 
some information to assist in the preparation of the new drug 
comments. The Editorial Executive Committee hopes this trend 
to increased transparency continues. 
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